Compounds > piperacillin
Page last updated: 2024-08-23

piperacillin and cefpodoxime

piperacillin has been researched along with cefpodoxime in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Arakawa, Y; Ishikawa, K; Nagano, N; Nagano, Y; Wachino, J1
Baptista, BC; Correia, JD; da Fonseca, JD; Martínez-Martínez, L; Pomba, C1
Boyd, DA; Mulvey, MR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for piperacillin and cefpodoxime

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for piperacillin and cefpodoxime

ArticleYear
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
    Journal of medicinal chemistry, 2005, Jun-30, Volume: 48, Issue:13

    Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1

    Topics: Amino Acid Sequence; beta-Lactamases; Blotting, Southern; Ceftazidime; Cephalosporins; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Shigella sonnei

2009
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence

2009
TEM-168, a heretofore laboratory-derived TEM beta-lactamase variant found in an Escherichia coli clinical isolate.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11

    Topics: Base Sequence; beta-Lactamases; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Sequence Data

2009